Abstract
Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.
©2014 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Comment
MeSH terms
-
Carbazoles / pharmacology*
-
Drug Resistance, Neoplasm / genetics*
-
Humans
-
Mutation*
-
Piperidines / pharmacology*
-
Protein Kinase Inhibitors / pharmacology*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor Protein-Tyrosine Kinases / genetics*
Substances
-
Carbazoles
-
Piperidines
-
Protein Kinase Inhibitors
-
Receptor Protein-Tyrosine Kinases